US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>First-Day Surge: VeraDermics priced above range at $17, doubled on open, peaked at $40.01, and closed at $37.75, marking a standout biotech IPO debut. </li>
<li>Anchor-Driven Demand: Wellington and Eli Lilly anchor orders catalyzed heavy institutional demand, driving an upsized deal and sharp first-day gains. </li>
<li>Post-IPO Caution: Elevated trading levels, concentrated ownership, and no Wellington lock-up suggest near-term volatility; traders should tread carefully.</li>
</ul>


First-Day Surge: VeraDermics priced above range at $17, doubled on open, peaked at $40.01, and closed at $37.75, marking a standout biotech IPO debut. 
Anchor-Driven Demand: Wellington and Eli Lilly anchor orders catalyzed heavy institutional demand, driving an upsized deal and sharp first-day gains. 
Post-IPO Caution: Elevated trading levels, concentrated ownership, and no Wellington lock-up suggest near-term volatility; traders should tread carefully.


Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO

<ul>
<li>Phase 2 biotech VeraDermics (MANE) targets pattern hair loss, offering 13.35 million shares at $14–$16 for a $467–$534 million valuation.</li>
<li>Wellington Management anchors up to $30 million, providing validation, as channel checks suggest oversubscription from testing-the-waters meetings.</li>
<li>Despite demand, competitive dermatology dynamics, single-asset risk, and a selective IPO market warrant a cautious investment stance.</li>
</ul>


Phase 2 biotech VeraDermics (MANE) targets pattern hair loss, offering 13.35 million shares at $14–$16 for a $467–$534 million valuation.
Wellington Management anchors up to $30 million, providing validation, as channel checks suggest oversubscription from testing-the-waters meetings.
Despite demand, competitive dermatology dynamics, single-asset risk, and a selective IPO market warrant a cautious investment stance.


Veradermics, Inc. (MANE): Wellington Anchors Dermatology Biotech but Caution Needed Around Subsector

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul>
<li>✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality &amp; Underwriters: 8/10 Veradermics is preparing to go public on the New York Stock Exchange under the symbol MANE through an initial public offering sized at approximately 13.4 million shares offered at a price range of $14 to $16 per share, implying roughly $190 million to $215 million raised before overallotment at the midpoint.</li>
<li>The company develops an extended-release oral formulation of minoxidil intended to treat pattern hair loss in both men and women and is currently positioned in Phase 2/3 and Phase 3 clinical trials to support a future regulatory filing.</li>
<li>This IPO aims to provide Veradermics with capital to advance pivotal studies, prepare commercial infrastructure, and support physician education for its lead candidate.</li>
</ul>


✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality &amp; Underwriters: 8/10 Veradermics is preparing to go public on the New York Stock Exchange under the symbol MANE through an initial public offering sized at approximately 13.4 million shares offered at a price range of $14 to $16 per share, implying roughly $190 million to $215 million raised before overallotment at the midpoint.
The company develops an extended-release oral formulation of minoxidil intended to treat pattern hair loss in both men and women and is currently positioned in Phase 2/3 and Phase 3 clinical trials to support a future regulatory filing.
This IPO aims to provide Veradermics with capital to advance pivotal studies, prepare commercial infrastructure, and support physician education for its lead candidate.


<ul><li>Veradermics, Inc. has set terms for its initial public offering as it looks to fund the late-stage development and potential commercialization of a novel oral treatment for pattern hair loss.</li><li>The company plans to offer 13.35 million shares at an expected price range of $14.00 to $16.00 per share , implying gross proceeds of roughly $200 million at the midpoint.</li><li>Based on approximately 33.35 million shares outstanding post-IPO, Veradermics would debut with an implied market capitalization of about $500 million and an enterprise value of approximately $320 million, assuming net cash raised from the offering.</li></ul>

Veradermics, Inc. has set terms for its initial public offering as it looks to fund the late-stage development and potential commercialization of a novel oral treatment for pattern hair loss.The company plans to offer 13.35 million shares at an expected price range of $14.00 to $16.00 per share , implying gross proceeds of roughly $200 million at the midpoint.Based on approximately 33.35 million shares outstanding post-IPO, Veradermics would debut with an implied market capitalization of about $500 million and an enterprise value of approximately $320 million, assuming net cash raised from the offering.

Veradermics Sets Terms for IPO as It Advances a Potential First-In-Class Oral Treatment

<ul>
<li>VeraDermics (MANE) seeks a $467–$534 million valuation, offering 13.35 million primary shares at $14–$16, with trading expected February 4.</li>
<li>Net proceeds of roughly $182 million are earmarked to advance VDPHL01 through NDA approval and initial U.S. commercialization.</li>
<li>Wellington Management anchors up to $30 million; Jefferies leads a smaller, sentiment-driven biotech IPO with concentrated institutional influence.</li>
</ul>


VeraDermics (MANE) seeks a $467–$534 million valuation, offering 13.35 million primary shares at $14–$16, with trading expected February 4.
Net proceeds of roughly $182 million are earmarked to advance VDPHL01 through NDA approval and initial U.S. commercialization.
Wellington Management anchors up to $30 million; Jefferies leads a smaller, sentiment-driven biotech IPO with concentrated institutional influence.


Veradermics, Inc. (MANE):Aesthetic & Dermatology Biotech Sets Terms Seeking up to $

United States

VeraDermics, Incorporated manufactures medical devices. The Company provides wart treatment with a kid-friendly drug delivery platform. VeraDermics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

VeraDermics (MANE US)

Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO

VeraDermics biotech IPO soars on first day with anchor-driven demand, but caution advised due to potential near-term volatility.

IPO Boutique

Veradermics, Inc. (MANE): Wellington Anchors Dermatology Biotech but Caution Needed Around Subsector

Biotech company VeraDermics targets pattern hair loss with IPO, but cautious investment stance advised due to competitive dynamics and single...

IPO Boutique

IPO Rating: Verademics, Inc.

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality & Underwriters: 8/10 Veradermics is preparing to go public on the New York Stock Exchange under...

IPO Prophet

Veradermics Sets Terms for IPO as It Advances a Potential First-In-Class Oral Treatment

Veradermics, Inc. has set terms for its initial public offering as it looks to fund the late-stage development and potential commercialization of...

IPO Prophet

Veradermics, Inc. (MANE):Aesthetic & Dermatology Biotech Sets Terms Seeking up to $

VeraDermics moves forward with its IPO, with proceeds to advance VDPHL01 for NDA approval and U.S. commercialization. Wellington Management to...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO

​VeraDermics biotech IPO soars on first day with anchor-driven demand, but caution advised due to potential near-term volatility.

IPO Boutique

Veradermics, Inc. (MANE): Wellington Anchors Dermatology Biotech but Caution Needed Around Subsector

​Biotech company VeraDermics targets pattern hair loss with IPO, but cautious investment stance advised due to competitive dynamics and single...

IPO Boutique

IPO Rating: Verademics, Inc.

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality & Underwriters: 8/10 Veradermics is preparing to go public on the New York Stock Exchange under...

IPO Prophet

Veradermics Sets Terms for IPO as It Advances a Potential First-In-Class Oral Treatment

Veradermics, Inc. has set terms for its initial public offering as it looks to fund the late-stage development and potential commercialization of...

IPO Prophet

Veradermics, Inc. (MANE):Aesthetic & Dermatology Biotech Sets Terms Seeking up to $

​VeraDermics moves forward with its IPO, with proceeds to advance VDPHL01 for NDA approval and U.S. commercialization. Wellington Management to...

IPO Boutique

VeraDermics biotech IPO soars on first day with anchor-driven demand, but caution advised due to potential near-term volatility.

Biotech company VeraDermics targets pattern hair loss with IPO, but cautious investment stance advised due to competitive dynamics and single...

VeraDermics moves forward with its IPO, with proceeds to advance VDPHL01 for NDA approval and U.S. commercialization. Wellington Management to...